Investigational Drug Details
| Drug ID: | D114 |
| Drug Name: | Loxapine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00408 |
| DrugBank Description: | An antipsychotic agent used in schizophrenia. [PubChem] |
| PubChem ID: | 3964 |
| CasNo: | 1977-10-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2 |
| Structure: |
|
| InChiKey: | XJGVXQDUIWGIRW-UHFFFAOYSA-N |
| Molecular Weight: | 327.808 |
| DrugBank Targets: | 5-hydroxytryptamine receptor 2A; Dopamine D2 receptor; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1E; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 5A; 5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 7; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Beta-1 adrenergic receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; D(1) dopamine receptor; Dopamine D3 receptor; Dopamine D4 receptor; Dopamine D5 receptor; Histamine H1 receptor; Histamine H2 receptor; Histamine H4 receptor; Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent dopamine transporter; Dopamine D1 receptor |
| DrugBank MoA: | Loxapine is a dopamine antagonist, and also a serotonin 5-HT2 blocker. The exact mode of action of Loxapine has not been established, however changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such manifestations of tranquilization as calming effects and suppression of aggressive behavior. |
| DrugBank Pharmacology: | Loxapine, a dibenzoxazepine compound, represents a subclass of tricyclic antipsychotic agents, chemically distinct from the thioxanthenes, butyrophenones, and phenothiazines. Pharmacologically, Loxapine is a tranquilizer for which the exact mode of action has not been established, however, it is believed that by antagonising dopamine and serotonin receptors, there is a marked cortical inhibition which can manifest as tranquilization and suppression of aggression. |
| DrugBank Indication: | For the management of the manifestations of psychotic disorders such as schizophrenia |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
